Exelixis Inc (EXEL) 6.28 $EXEL
This Explains Exelixis' METEOR-ic Rise in July
Sean Williams, The Motley Fool - Motley Fool - Wed Aug 05, 9:18AM CDT
Shares of Exelixis , a biotech company focused on developing therapies to combat cancer, galloped higher by 52% in the month of July based on data from S&P Capital IQ after announcing positive top-line data from its METEOR trial and raising...
EXEL: 6.28 (-0.34)
Exelixis (EXEL) Shows Strength: Stock Adds 8.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 05, 7:51AM CDT
Exelixis, Inc. (EXEL) was a big mover last session, as its shares rose over 8% on the day.
EXEL: 6.28 (-0.34)
Critical Alerts For PayPal Holdings Inc., Exelixis, Glu Mobile, Clorox and AbbVie Released By InvestorsObserver
PR Newswire - Tue Aug 04, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for PYPL, EXEL, GLUU, CLX and ABBV.
CLX: 118.94 (+2.09), ABBV: 70.30 (+0.35), PYPL: 39.27 (+0.32), GLUU: 4.50 (-1.17), EXEL: 6.28 (-0.34)
'Mad Money' Lightning Round: Marriott International Is a Buy
at The Street - Tue Aug 04, 5:00AM CDT
Cramer says he can't recommend CenturyLink but likes VeriFone and Blackhawk Network.
AMBA: 115.05 (+0.40), HAWK: 45.45 (-0.14), PAY: 32.96 (+0.38), MAR: 70.70 (-1.52), CTL: 28.56 (+0.13), EXEL: 6.28 (-0.34), ARRY: 6.10 (+0.29)
Jim Cramer's 'Mad Money' Recap: Why the Oil and China News Isn't All Bad
at The Street - Mon Aug 03, 7:41PM CDT
There are two sides to every story, Cramer says.
AMBA: 115.05 (+0.40), KR: 39.08 (+0.52), FRPT: 17.37 (+0.32), XOM: 77.17 (unch), WMT: 73.51 (+1.26), MAR: 70.70 (-1.52), DEO: 113.95 (+1.86), IMAX: 37.98 (+0.57), BUFF: 27.78 (-0.20), RDS.A: 57.71 (+0.61), GM: 31.60 (+0.08), HAWK: 45.45 (-0.14), PAY: 32.96 (+0.38), CVX: 84.03 (-1.18), AAPL: 115.40 (+0.76), BRX: 24.48 (-0.15), CTL: 28.56 (+0.13), ARRY: 6.10 (+0.29), EXEL: 6.28 (-0.34)
Small-Cell Lung Cancer - Pipeline Review, H1 2015
M2 - Fri Jul 31, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/szb6j5/smallcell_lung) has announced the addition of the "Small-Cell Lung Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Partial List - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Alchemia Limited - Amgen Inc. - Aposense Ltd. - Array BioPharma Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bayer AG - BIND Therapeutics, Inc. - Blend Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Cantex Pharmaceuticals, Inc. - Celator Pharmaceuticals, Inc. - CellAct Pharma GmbH - Cerulean Pharma, Inc. - Cornerstone Pharmaceuticals, Inc. - Critical Outcome Technologies Inc. - CytRx Corporation - Eisai Co., Ltd. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Hutchison MediPharma Limited - ImmunoCellular Therapeutics, Ltd. - Immunomedics, Inc. - Inbiopro Solutions Pvt. Ltd For more information visit http://www.researchandmarkets.com/research/sz...lcell_lung
IMMU: 2.06 (-0.01), CERU: 3.95 (-0.12), AMGN: 176.44 (+1.64), LLY: 84.73 (+0.68), BIND: 4.58 (-0.13), GSK: 44.17 (+0.72), BMY: 65.06 (+0.22), IMUC: 0.46 (-0.01), AZN: 34.54 (+0.20), CYTR: 2.62 (-0.04), AVEO: 1.41 (-0.03), ABBV: 70.30 (+0.35), EXEL: 6.28 (-0.34), ARRY: 6.10 (+0.29)
Renal Cell Carcinoma Pipeline Review, H1 2015 - 81 Companies & 130 Drug Profiles
M2 - Fri Jul 31, 8:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cmjmhc/renal_cell) has announced the addition of the "Renal Cell Carcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development: 35 of the 81 Companies Featured - Acceleron Pharma, Inc. - Advenchen Laboratories, LLC - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Angiogene Pharmaceuticals Limited - arGEN-X BV - Argos Therapeutics, Inc. - Astellas Pharma Inc. - Bayer AG - Beta Pharma, Inc. - Bio-Cancer Treatment International Limited - Biogenomics Limited - Bionomics Limited - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Calithera Biosciences, Inc. - Celldex Therapeutics, Inc. - Celltrion, Inc. - Cerulean Pharma, Inc. - Chipscreen Biosciences Ltd - Conkwest, Inc. - CureTech Ltd. - Cytune Pharma SAS - Eisai Co., Ltd. - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Genor BioPharma Co., Ltd. - GenSpera, Inc. - GlaxoSmithKline Plc For more information visit http://www.researchandmarkets.com/research/cmjmhc/renal_cell
CERU: 3.95 (-0.12), AMBX: (), CLDX: 23.56 (+0.26), AMGN: 176.44 (+1.64), LLY: 84.73 (+0.68), AMPE: 2.48 (+0.03), GSK: 44.17 (+0.72), BMY: 65.06 (+0.22), CLBS: 1.58 (-0.01), ARGS: 6.05 (-0.01), NK: 31.48 (+1.48), CALA: 6.93 (-0.21), EXEL: 6.28 (-0.34), XLRN: 28.86 (-0.15)
What to Expect from Exelixis (EXEL) This Earnings Season? (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 29, 3:36PM CDT
The company has an impressive track record, having beat estimates comfortably in the last four quarters. It posted a positive average earnings surprise of 11.61% in the last four quarters.
MNK: 104.51 (-2.22), PRGO: 189.65 (-0.99), TEVA: 71.19 (+0.50), EXEL: 6.28 (-0.34)
Can the Rally in Exelixis (EXEL) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 29, 5:46AM CDT
Can the Rally in Exelixis (EXEL) Shares Continue?
EXEL: 6.28 (-0.34)
Exelixis to Release Second Quarter 2015 Financial Results on Tuesday, August 11, 2015
Business Wire - Tue Jul 28, 3:34PM CDT
Exelixis, Inc. (NASDAQ: EXEL) announced today that its second quarter 2015 financial results will be released on Tuesday, August 11, 2015 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call to discuss the results and provide a general business update. The conference call will be accessible via the Internet from the company's website.
EXEL: 6.28 (-0.34)
What to Expect from Exelixis (EXEL) This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 2:00PM CDT
Exelixis (EXEL) has a Zacks Rank #2 with an earnings ESP of -9.52% and is expected to report second-quarter 2015 results on Jul 30.
MNK: 104.51 (-2.22), PRGO: 189.65 (-0.99), TEVA: 71.19 (+0.50), EXEL: 6.28 (-0.34)
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis
BLUE: 166.51 (+2.04), BIIB: 335.41 (+5.03), LGND: 111.25 (+1.94), REGN: 592.40 (+11.46), EXEL: 6.28 (-0.34)
Exelixis (EXEL) Stock Falls on Upsized Secondary Offering
at The Street - Mon Jul 27, 2:43PM CDT
Exelexis (EXEL) shares are down after the company added 5 million shares to its secondary offering.
EXEL: 6.28 (-0.34)
Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 166.51 (+2.04), BIIB: 335.41 (+5.03), LGND: 111.25 (+1.94), AMGN: 176.44 (+1.64), REGN: 592.40 (+11.46), EXEL: 6.28 (-0.34), CELG: 132.72 (+1.64)
Medullary Thyroid Cancer - Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ldtm6m/medullary_thyroid) has announced the addition of the "Medullary Thyroid Cancer Global Clinical Trials Review, H1, 2015" report to their offering. "Medullary Thyroid Cancer Global Clinical Trials Review, H1, 2015" provides data on the Medullary Thyroid Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Medullary Thyroid Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Medullary Thyroid Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Medullary Thyroid Cancer Therapeutics Clinical Trials - AstraZeneca PLC - Exelixis, Inc. - Eisai Co., Ltd. - Sino Biopharmaceutical Limited - Sanofi - Immunomedics, Inc. - Globeimmune, Inc. - EANM Research Ltd. - Bayer AG - Amgen Inc. - National Cancer Institute - University of Kentucky - University of Wisconsin Madison - Garden State Cancer Center - University of Texas M. D. Anderson Cancer Center - University of Southern California - Sidney Kimmel Comprehensive Cancer Center - University of Washington - Medical University of Vienna - Leiden University Medical Center For more information visit http://www.researchandmarkets.com/research/ld...ry_thyroid
IMMU: 2.06 (-0.01), AZN: 34.54 (+0.20), AMGN: 176.44 (+1.64), EXEL: 6.28 (-0.34)
3 Biotech Stocks That Could Double Before 2016
George Budwell, Sean Williams, and Todd Campbell, The Motley Fool - Motley Fool - Sun Jul 26, 7:54AM CDT
Small-cap biotech stocks have the ability to produce eye-popping gains -- and even double, in short order. In the same breath, they also have the capacity to wreak havoc on your portfolio if things go the wrong way in the clinic or on the regulatory...
ONCE: 57.50 (-6.99), GERN: 4.02 (+0.02), EXEL: 6.28 (-0.34)
How to Trade 4 of the Market's Most Active Stocks
at The Street - Fri Jul 24, 1:45PM CDT
Here's a technical look at how to trade some of the most actives stocks on the market right now.
AMZN: 537.01 (+5.11), P: 17.81 (+0.03), GDX: 13.09 (-0.20), EXEL: 6.28 (-0.34)
Positive Results From Phase 3 Clinical Trial of Cabozantinib - Report on Exelixis
PR Newswire - Fri Jul 24, 8:05AM CDT
ACI Association has initiated research coverage on Exelixis, Inc. (NASDAQ: EXEL). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.
EXEL: 6.28 (-0.34)
Exelixis prices public offering of common stock at USD5.40 per share
M2 - Fri Jul 24, 5:22AM CDT
Biopharmaceutical company Exelixis (Nasdaq:EXEL) said on Thursday that it has priced its public offering of 25,000,000 shares of its newly issued common stock.
EXEL: 6.28 (-0.34)
Exelixis Prices Public Offering of Common Stock
Business Wire - Thu Jul 23, 7:08PM CDT
Exelixis, Inc. (Nasdaq:EXEL) today announced the pricing of its underwritten public offering of 25,000,000 shares of newly issued common stock at a price to the public of $5.40 per share. The gross proceeds to Exelixis from this offering are expected to be approximately $135 million, before deducting the underwriting discount and other estimated offering expenses payable by Exelixis. Exelixis also granted the underwriters a 30-day option to purchase up to an additional 3,750,000 shares of its common stock. All of the shares are being sold by Exelixis.
EXEL: 6.28 (-0.34)
This Explains Exelixis' METEOR-ic Rise in July
Sean Williams, The Motley Fool - Motley Fool - Wed Aug 05, 9:18AM CDT
Shares of Exelixis , a biotech company focused on developing therapies to combat cancer, galloped higher by 52% in the month of July based on data from S&P Capital IQ after announcing positive top-line data from its METEOR trial and raising...
EXEL: 6.28 (-0.34)
Exelixis (EXEL) Shows Strength: Stock Adds 8.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 05, 7:51AM CDT
Exelixis, Inc. (EXEL) was a big mover last session, as its shares rose over 8% on the day.
EXEL: 6.28 (-0.34)
Critical Alerts For PayPal Holdings Inc., Exelixis, Glu Mobile, Clorox and AbbVie Released By InvestorsObserver
PR Newswire - Tue Aug 04, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for PYPL, EXEL, GLUU, CLX and ABBV.
CLX: 118.94 (+2.09), ABBV: 70.30 (+0.35), PYPL: 39.27 (+0.32), GLUU: 4.50 (-1.17), EXEL: 6.28 (-0.34)
'Mad Money' Lightning Round: Marriott International Is a Buy
at The Street - Tue Aug 04, 5:00AM CDT
Cramer says he can't recommend CenturyLink but likes VeriFone and Blackhawk Network.
AMBA: 115.05 (+0.40), HAWK: 45.45 (-0.14), PAY: 32.96 (+0.38), MAR: 70.70 (-1.52), CTL: 28.56 (+0.13), EXEL: 6.28 (-0.34), ARRY: 6.10 (+0.29)
Jim Cramer's 'Mad Money' Recap: Why the Oil and China News Isn't All Bad
at The Street - Mon Aug 03, 7:41PM CDT
There are two sides to every story, Cramer says.
AMBA: 115.05 (+0.40), KR: 39.08 (+0.52), FRPT: 17.37 (+0.32), XOM: 77.17 (unch), WMT: 73.51 (+1.26), MAR: 70.70 (-1.52), DEO: 113.95 (+1.86), IMAX: 37.98 (+0.57), BUFF: 27.78 (-0.20), RDS.A: 57.71 (+0.61), GM: 31.60 (+0.08), HAWK: 45.45 (-0.14), PAY: 32.96 (+0.38), CVX: 84.03 (-1.18), AAPL: 115.40 (+0.76), BRX: 24.48 (-0.15), CTL: 28.56 (+0.13), ARRY: 6.10 (+0.29), EXEL: 6.28 (-0.34)
Small-Cell Lung Cancer - Pipeline Review, H1 2015
M2 - Fri Jul 31, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/szb6j5/smallcell_lung) has announced the addition of the "Small-Cell Lung Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Partial List - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Alchemia Limited - Amgen Inc. - Aposense Ltd. - Array BioPharma Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bayer AG - BIND Therapeutics, Inc. - Blend Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Cantex Pharmaceuticals, Inc. - Celator Pharmaceuticals, Inc. - CellAct Pharma GmbH - Cerulean Pharma, Inc. - Cornerstone Pharmaceuticals, Inc. - Critical Outcome Technologies Inc. - CytRx Corporation - Eisai Co., Ltd. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Hutchison MediPharma Limited - ImmunoCellular Therapeutics, Ltd. - Immunomedics, Inc. - Inbiopro Solutions Pvt. Ltd For more information visit http://www.researchandmarkets.com/research/sz...lcell_lung
IMMU: 2.06 (-0.01), CERU: 3.95 (-0.12), AMGN: 176.44 (+1.64), LLY: 84.73 (+0.68), BIND: 4.58 (-0.13), GSK: 44.17 (+0.72), BMY: 65.06 (+0.22), IMUC: 0.46 (-0.01), AZN: 34.54 (+0.20), CYTR: 2.62 (-0.04), AVEO: 1.41 (-0.03), ABBV: 70.30 (+0.35), EXEL: 6.28 (-0.34), ARRY: 6.10 (+0.29)
Renal Cell Carcinoma Pipeline Review, H1 2015 - 81 Companies & 130 Drug Profiles
M2 - Fri Jul 31, 8:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cmjmhc/renal_cell) has announced the addition of the "Renal Cell Carcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development: 35 of the 81 Companies Featured - Acceleron Pharma, Inc. - Advenchen Laboratories, LLC - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Angiogene Pharmaceuticals Limited - arGEN-X BV - Argos Therapeutics, Inc. - Astellas Pharma Inc. - Bayer AG - Beta Pharma, Inc. - Bio-Cancer Treatment International Limited - Biogenomics Limited - Bionomics Limited - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Calithera Biosciences, Inc. - Celldex Therapeutics, Inc. - Celltrion, Inc. - Cerulean Pharma, Inc. - Chipscreen Biosciences Ltd - Conkwest, Inc. - CureTech Ltd. - Cytune Pharma SAS - Eisai Co., Ltd. - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Genor BioPharma Co., Ltd. - GenSpera, Inc. - GlaxoSmithKline Plc For more information visit http://www.researchandmarkets.com/research/cmjmhc/renal_cell
CERU: 3.95 (-0.12), AMBX: (), CLDX: 23.56 (+0.26), AMGN: 176.44 (+1.64), LLY: 84.73 (+0.68), AMPE: 2.48 (+0.03), GSK: 44.17 (+0.72), BMY: 65.06 (+0.22), CLBS: 1.58 (-0.01), ARGS: 6.05 (-0.01), NK: 31.48 (+1.48), CALA: 6.93 (-0.21), EXEL: 6.28 (-0.34), XLRN: 28.86 (-0.15)
What to Expect from Exelixis (EXEL) This Earnings Season? (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 29, 3:36PM CDT
The company has an impressive track record, having beat estimates comfortably in the last four quarters. It posted a positive average earnings surprise of 11.61% in the last four quarters.
MNK: 104.51 (-2.22), PRGO: 189.65 (-0.99), TEVA: 71.19 (+0.50), EXEL: 6.28 (-0.34)
Can the Rally in Exelixis (EXEL) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 29, 5:46AM CDT
Can the Rally in Exelixis (EXEL) Shares Continue?
EXEL: 6.28 (-0.34)
Exelixis to Release Second Quarter 2015 Financial Results on Tuesday, August 11, 2015
Business Wire - Tue Jul 28, 3:34PM CDT
Exelixis, Inc. (NASDAQ: EXEL) announced today that its second quarter 2015 financial results will be released on Tuesday, August 11, 2015 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call to discuss the results and provide a general business update. The conference call will be accessible via the Internet from the company's website.
EXEL: 6.28 (-0.34)
What to Expect from Exelixis (EXEL) This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 2:00PM CDT
Exelixis (EXEL) has a Zacks Rank #2 with an earnings ESP of -9.52% and is expected to report second-quarter 2015 results on Jul 30.
MNK: 104.51 (-2.22), PRGO: 189.65 (-0.99), TEVA: 71.19 (+0.50), EXEL: 6.28 (-0.34)
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis
BLUE: 166.51 (+2.04), BIIB: 335.41 (+5.03), LGND: 111.25 (+1.94), REGN: 592.40 (+11.46), EXEL: 6.28 (-0.34)
Exelixis (EXEL) Stock Falls on Upsized Secondary Offering
at The Street - Mon Jul 27, 2:43PM CDT
Exelexis (EXEL) shares are down after the company added 5 million shares to its secondary offering.
EXEL: 6.28 (-0.34)
Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 166.51 (+2.04), BIIB: 335.41 (+5.03), LGND: 111.25 (+1.94), AMGN: 176.44 (+1.64), REGN: 592.40 (+11.46), EXEL: 6.28 (-0.34), CELG: 132.72 (+1.64)
Medullary Thyroid Cancer - Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ldtm6m/medullary_thyroid) has announced the addition of the "Medullary Thyroid Cancer Global Clinical Trials Review, H1, 2015" report to their offering. "Medullary Thyroid Cancer Global Clinical Trials Review, H1, 2015" provides data on the Medullary Thyroid Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Medullary Thyroid Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Medullary Thyroid Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Medullary Thyroid Cancer Therapeutics Clinical Trials - AstraZeneca PLC - Exelixis, Inc. - Eisai Co., Ltd. - Sino Biopharmaceutical Limited - Sanofi - Immunomedics, Inc. - Globeimmune, Inc. - EANM Research Ltd. - Bayer AG - Amgen Inc. - National Cancer Institute - University of Kentucky - University of Wisconsin Madison - Garden State Cancer Center - University of Texas M. D. Anderson Cancer Center - University of Southern California - Sidney Kimmel Comprehensive Cancer Center - University of Washington - Medical University of Vienna - Leiden University Medical Center For more information visit http://www.researchandmarkets.com/research/ld...ry_thyroid
IMMU: 2.06 (-0.01), AZN: 34.54 (+0.20), AMGN: 176.44 (+1.64), EXEL: 6.28 (-0.34)
3 Biotech Stocks That Could Double Before 2016
George Budwell, Sean Williams, and Todd Campbell, The Motley Fool - Motley Fool - Sun Jul 26, 7:54AM CDT
Small-cap biotech stocks have the ability to produce eye-popping gains -- and even double, in short order. In the same breath, they also have the capacity to wreak havoc on your portfolio if things go the wrong way in the clinic or on the regulatory...
ONCE: 57.50 (-6.99), GERN: 4.02 (+0.02), EXEL: 6.28 (-0.34)
How to Trade 4 of the Market's Most Active Stocks
at The Street - Fri Jul 24, 1:45PM CDT
Here's a technical look at how to trade some of the most actives stocks on the market right now.
AMZN: 537.01 (+5.11), P: 17.81 (+0.03), GDX: 13.09 (-0.20), EXEL: 6.28 (-0.34)
Positive Results From Phase 3 Clinical Trial of Cabozantinib - Report on Exelixis
PR Newswire - Fri Jul 24, 8:05AM CDT
ACI Association has initiated research coverage on Exelixis, Inc. (NASDAQ: EXEL). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.
EXEL: 6.28 (-0.34)
Exelixis prices public offering of common stock at USD5.40 per share
M2 - Fri Jul 24, 5:22AM CDT
Biopharmaceutical company Exelixis (Nasdaq:EXEL) said on Thursday that it has priced its public offering of 25,000,000 shares of its newly issued common stock.
EXEL: 6.28 (-0.34)
Exelixis Prices Public Offering of Common Stock
Business Wire - Thu Jul 23, 7:08PM CDT
Exelixis, Inc. (Nasdaq:EXEL) today announced the pricing of its underwritten public offering of 25,000,000 shares of newly issued common stock at a price to the public of $5.40 per share. The gross proceeds to Exelixis from this offering are expected to be approximately $135 million, before deducting the underwriting discount and other estimated offering expenses payable by Exelixis. Exelixis also granted the underwriters a 30-day option to purchase up to an additional 3,750,000 shares of its common stock. All of the shares are being sold by Exelixis.
EXEL: 6.28 (-0.34)
